Omalizumab in chronic spontaneous urticaria: patient-tailored tapering or planned discontinuation?

Ann Allergy Asthma Immunol. 2015 Aug;115(2):147-8. doi: 10.1016/j.anai.2015.05.005. Epub 2015 Jun 2.

Authors

Chiara Tontini¹, Lucia Marinangeli², Miriam Cognigni², Maria Beatrice Bilò², Leonardo Antonicelli²

Affiliations

¹ Department of Internal Medicine, Allergy Unit, Azienda Ospedaliero-Universitaria Ospedali Riuniti, Ancona, Italy. Electronic address: c.tontini@live.com.
² Department of Internal Medicine, Allergy Unit, Azienda Ospedaliero-Universitaria Ospedali Riuniti, Ancona, Italy.

PMID: 26048249
DOI: 10.1016/j.anai.2015.05.005

No abstract available

Publication types

Letter

MeSH terms

Adrenal Cortex Hormones / therapeutic use
Adult
Anti-Allergic Agents / therapeutic use*
Antibodies, Anti-Idiotypic / therapeutic use*
Antibodies, Monoclonal, Humanized / therapeutic use*
Chronic Disease
Desensitization, Immunologic
Drug Administration Schedule
Drug Dosage Calculations
Female
Humans
Male
Middle Aged
Omalizumab
Practice Guidelines as Topic
Precision Medicine
Prednisone / therapeutic use
Severity of Illness Index
Urticaria / drug therapy*
Urticaria / immunology
Urticaria / physiopathology

Substances

Adrenal Cortex Hormones
Anti-Allergic Agents
Antibodies, Anti-Idiotypic
Antibodies, Monoclonal, Humanized
Omalizumab
Prednisone